---
title: "Humira (adalimumab), all indications: Pharmacology questions"
description: "Pharmacology questions on Humira (adalimumab) that apply to every indication, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Mechanism, Pharmacokinetics, and Components. Questions: How does Humira work (mechanism of action)? How long does Humira stay in your system (half-life)? How is Humira cleared from the body? How quickly is Humira absorbed after a subcutaneous injection? 1 further question follow. 5 questions quoted from 1 source."
canonical: "https://www.evicenter.com/medical-information/humira/pharmacology"
published: "2026-11-14T01:54:55-05:00"
modified: "2026-11-14T01:54:55-05:00"
---

# Humira (adalimumab), all indications: Pharmacology questions

Manufacturer: AbbVie Inc.  
Prescribing information: [Humira](https://www.rxabbvie.com/pdf/humira.pdf)  
Indication pages: [Rheumatoid arthritis](https://www.evicenter.com/medical-information/humira--rheumatoid-arthritis)

## Mechanism

<a id="humira-mechanism"></a>

### How does Humira work (mechanism of action)?

> “12.1 Mechanism of Action 
> Adalimumab binds specifically to TNF-alpha and blocks its interaction with the p55 and p75 cell 
> surface TNF receptors. Adalimumab also lyses surface TNF expressing cells in vitro in the 
> presence of complement. Adalimumab does not bind or inactivate lymphotoxin (TNF-beta). TNF 
> is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. 
> Elevated concentrations of TNF are found in the synovial fluid of patients with RA, JIA, PsA, 
> and AS and play an important role in both the pathologic inflammation and the joint destruction 
> that are hallmarks of these diseases.”

Source: [HUMIRA: Prescribing information, page 28, captured 2026-11-13](https://www.rxabbvie.com/pdf/humira.pdf#page=28)

> “Adalimumab also modulates biological responses that are induced or regulated by TNF, 
> including changes in the concentrations of adhesion molecules responsible for leukocyte 
> migration (ELAM-1, VCAM-1, and ICAM-1 with an IC50 of 1-2 X 10-10M).”

Source: [HUMIRA: Prescribing information, page 29, captured 2026-11-13](https://www.rxabbvie.com/pdf/humira.pdf#page=29)

## Pharmacokinetics

<a id="humira-half-life"></a>

### How long does Humira stay in your system (half-life)?

> “The mean terminal half-life was 
> approximately 2 weeks, ranging from 10 to 20 days across studies.”

Source: [HUMIRA: Prescribing information, page 29, captured 2026-11-13](https://www.rxabbvie.com/pdf/humira.pdf#page=29)

<a id="humira-elimination"></a>

### How is Humira cleared from the body?

> “Elimination 
> The single dose pharmacokinetics of adalimumab in RA patients were determined in several 
> studies with intravenous doses ranging from 0.25 to 10 mg/kg. The systemic clearance of”

Source: [HUMIRA: Prescribing information, page 29, captured 2026-11-13](https://www.rxabbvie.com/pdf/humira.pdf#page=29)

> “adalimumab is approximately 12 mL/hr. In long-term studies with dosing more than two years, 
> there was no evidence of changes in clearance over time in RA patients.”

Source: [HUMIRA: Prescribing information, page 30, captured 2026-11-13](https://www.rxabbvie.com/pdf/humira.pdf#page=30)

> “Rheumatoid Arthritis: A trend toward higher apparent clearance of adalimumab in the presence 
> of anti-adalimumab antibodies was identified.”

Source: [HUMIRA: Prescribing information, page 30, captured 2026-11-13](https://www.rxabbvie.com/pdf/humira.pdf#page=30)

> “Methotrexate: MTX reduced adalimumab apparent clearance after single and multiple dosing by 
> 29% and 44% respectively, in patients with RA [see Drug Interactions (7.1)].”

Source: [HUMIRA: Prescribing information, page 32, captured 2026-11-13](https://www.rxabbvie.com/pdf/humira.pdf#page=32)

Note: The label gives clearance values and does not describe a metabolic pathway for adalimumab. The first passage ends with the opening words of a sentence at the foot of page 29 of the Prescribing Information; the second passage completes it on page 30.

<a id="humira-absorption"></a>

### How quickly is Humira absorbed after a subcutaneous injection?

> “The average absolute bioavailability of adalimumab following a single 40 mg subcutaneous dose 
> was 64%. The mean time to reach the maximum concentration was 5.5 days (131 ± 56 hours) 
> and the maximum serum concentration was 4.7 ± 1.6 mcg/mL in healthy subjects following a 
> single 40 mg subcutaneous administration of HUMIRA.”

Source: [HUMIRA: Prescribing information, page 29, captured 2026-11-13](https://www.rxabbvie.com/pdf/humira.pdf#page=29)

## Components

<a id="humira-inactive-ingredients"></a>

### What are the inactive ingredients in Humira?

> “HUMIRA (adalimumab) injection is supplied as a sterile, preservative-free solution for 
> subcutaneous administration. The drug product is supplied as either a single-dose, prefilled pen 
> (HUMIRA Pen) or as a single-dose, 1 mL prefilled glass syringe. Enclosed within the pen is a 
> single-dose, 1 mL prefilled glass syringe. The solution of HUMIRA is clear and colorless, with a 
> pH of about 5.2.  
> Each 80 mg/0.8 mL prefilled syringe or prefilled pen delivers 0.8 mL (80 mg) of drug product. 
> Each 0.8 mL of HUMIRA contains adalimumab (80 mg), mannitol (33.6 mg), polysorbate 80 
> (0.8 mg), and Water for Injection, USP.  
> Each 40 mg/0.4 mL prefilled syringe or prefilled pen delivers 0.4 mL (40 mg) of drug product. 
> Each 0.4 mL of HUMIRA contains adalimumab (40 mg), mannitol (16.8 mg), polysorbate 80 
> (0.4 mg), and Water for Injection, USP.  
> Each 40 mg/0.8 mL prefilled syringe or prefilled pen delivers 0.8 mL (40 mg) of drug product. 
> Each 0.8 mL of HUMIRA contains adalimumab (40 mg), citric acid monohydrate (1.04 mg), 
> dibasic sodium phosphate dihydrate (1.22 mg), mannitol (9.6 mg), monobasic sodium phosphate 
> dihydrate (0.69 mg), polysorbate 80 (0.8 mg), sodium chloride (4.93 mg), sodium citrate (0.24 
> mg) and Water for Injection, USP. Sodium hydroxide is added as necessary to adjust pH.  
> Each 20 mg/0.2 mL prefilled syringe delivers 0.2 mL (20 mg) of drug product. Each 0.2 mL of 
> HUMIRA contains adalimumab (20 mg), mannitol (8.4 mg), polysorbate 80 (0.2 mg), and Water 
> for Injection, USP.  
> Each 10 mg/0.1 mL prefilled syringe delivers 0.1 mL (10 mg) of drug product. Each 0.1 mL of 
> HUMIRA contains adalimumab (10 mg), mannitol (4.2 mg), polysorbate 80 (0.1 mg), and Water 
> for Injection, USP.”

Source: [HUMIRA: Prescribing information, page 28, captured 2026-11-13](https://www.rxabbvie.com/pdf/humira.pdf#page=28)

## Related pages
- [Medical information: Humira (adalimumab): All indications](https://www.evicenter.com/medical-information/humira)
- [Indication](https://www.evicenter.com/medical-information/humira/indication)
- [Safety](https://www.evicenter.com/medical-information/humira/safety)
- [Specific populations](https://www.evicenter.com/medical-information/humira/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/humira/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/humira/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/humira/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/humira/access-and-coverage)
